Genmab A/S, of Copenhagen, Denmark, reported that South San Francisco-based Genentech Inc., a unit of the Roche Group, and Weston, Mass.-based Biogen Idec Inc

The Royalty offer is contingent on Elan's shareholders voting down all of its M&A transactions, including its recent $1 billion cash deal to buy a 21 percent stake in South San Francisco-based Theravance Inc.'s future royalty stream from the respiratory franchise it shares with London-based GlaxoSmithKline plc

The Royalty offer is contingent on Elan's shareholders voting down all of its M&A transactions, including its recent $1 billion cash deal to buy a 21 percent stake in South San Francisco-based Theravance Inc.'s future royalty stream from the respiratory franchise it shares with London-based GlaxoSmithKline plc

Inc. (Whitehouse Station, N.J.) $86.5 Exercised option for Merck to exclusively license small-molecule compounds for a target in cardiovascular disease The companies inked the deal in 2009, and under the terms, Xenon received milestone payments and an option fee and is eligible for further research, development and regulatory milestone payments of up to $86.5M 4/18/13 MAY Hyperion Therapeutics Inc. (South San Francisco) Valeant Pharmaceuticals International Inc. (Montreal) $13-$22 Hyperion

Genmab A/S, of Copenhagen, Denmark, reported that South San Francisco-based Genentech Inc., a unit of the Roche Group, and Weston, Mass.-based Biogen Idec Inc

Bayer HealthCare Pharmaceuticals Inc., of Berkeley, Calif., and Onyx Pharmaceuticals Inc., of South San Francisco, said the FDA approved Bayer's Stivarga (regorafenib) for metastatic gastrointestinal stromal tumor previously treated with imatinib mesylate and sunitinib malate

Daniel S. Chen, associate group director and global development team leader for the anti-PD-L1 program at South San Francisco-based Genentech, agreed that targeting PD-L1 represents cutting-edge cancer therapeutic development

The deal implies a valuation of $4.76 billion for Theravance's future royalty income from the four-product franchise, which suggests that the market considerably undervalues the South San Francisco-based biotech firm

The deal implies a valuation of $4.76 billion for Theravance's future royalty income from the four-product franchise, which suggests that the market considerably undervalues the South San Francisco-based biotech firm

South San Francisco) Cometriq Cabozantinib Castration-resistant prostate cancer Bone metastases showed a 67% rate of bone scan response and other clinical signs of effect 4/12/13 Onconova Therapeutics Inc. (Newtown, Pa.) Rigosertib A dual pathway inhibitor Solid tumors Phase I data showed tolerability and favorable antitumor activity 4/11/13 Pharmacyclics Inc. (Sunnyvale, Calif.) Ibrutinib Oral agent Chronic lymphocytic leukemia Phase II data showed that 95% of patients experienced a reduction

South San Francisco) Zybrestat Antiangiogenic therapeutic

South San Francisco-based Theravance's shares (NASDAQ:THRX) jumped 11.6 percent on news from the FDA, closing Friday at $34.94, up $3.63

Kadcyla is marketed by Roche AG unit Genentech Inc., of South San Francisco

South San Francisco) CK-2127107 Molecule activator of the fast skeletal muscle troponin complex Conditions associated with neuromuscular dysfunction, muscular weakness and/or muscle fatigue Started a Phase I trial 4/2/13 Immunomic Therapeutics Inc. (Lancaster, Pa.) JRC-LAMP-vax Immunothera-peutic vaccine Red cedar allergy Phase I data showed it met all of its primary safety endpoints 4/25/13 Lipocine Inc. (Salt Lake City) LPCN 1111 Next-generation oral testosterone replacement product

Company (Location) Product Description Indication Status Date AUTOIMMUNE Rigel Pharmaceuticals Inc. (South San Francisco) and AstraZeneca plc (London) Fostamatinib Oral spleen tyrosine kinase inhibitor Rheumatoid arthritis Missed the X-ray endpoint of modified Total Sharp score, but hit statistical significance in ACR20 scoring, although the Phase III still fell short of those achieved by Pfizer Inc.'s approved Xeljanz 4/8/13 CANCER Array BioPharma Inc. (Boulder, Colo.) ARRY-520 A selective KSP

Curis earned a $4 million milestone payment from Genentech Inc., of South San Francisco (a unit of Roche AG), as a result of the Australian approval

South San Francisco) and GlaxoSmithKline plc (London) UMEC/VI A combination of GSK573719, or umeclidinium bromide, a long-acting muscarinic antagonist, and vilanterol, a long-acting beta2 agonist, administered using the ELLIPTA inhaler Chronic obstructive pulmonary disease Submitted a regulatory application in Japan 4/23/13 MISCELLANEOUS Advanced Cell Technology Inc. (Marlborough, Mass.) hESC-RPE Human embryonic stem cell-derived retinal pigment epithelial cells Stargardt's macular dystrophy The

South San Francisco) and GlaxoSmithKline plc (London) Breo Fluticasone furoate (FF)/vilanterol (VI), the combination corticosteroid and long-acting beta2 agonist Chronic obstructive pulmonary disease FDA committee recommended approval 4/18/13 Tris Pharma Inc. (Monmouth Junction, N.J.) Karbinal ER Carbinoxamine maleate extended-release oral suspension Seasonal and perennial allergic rhinitis FDA approved it 4/4/13 MISCELLANEOUS Enlivex Therapeutics Ltd. (Jerusalem) ApoCell A treatment based on

Exelixis Inc. , of South San Francisco, reported net revenues for the quarter ended March 31, 2013, were $9.7 million, compared to $18.5 million for the comparable period in 2012...Onyx Pharmaceuticals Inc. , of South San Francisco, reported a doubling of its total revenues to $145.5 million in its financial results for the first quarter 2013, as compared to total revenue of $72 million for the comparable period in 2012